ILMN vs DHR vs RVTY Stock Comparison

Illumina, Danaher and Revvity Prices as of Oct 28, 2026 Peers: Industry group
ILMN Illumina, Inc.
$288.79 +6.2% 1M +195.3% 1Y
Market cap
$43.30B
P/E
52.5x
Revenue (TTM)
$4.49B
Div. yield
–
Life Sciences Tools Healthcare
6 wins
DHR Danaher Corp /De/
$234.09 +2.9% 1M +7.9% 1Y
Market cap
$165.93B
P/E
41.4x
Revenue (TTM)
$25.11B
Div. yield
–
Life Sciences Tools Healthcare
4 wins
RVTY Revvity, Inc.
$165.36 +9.5% 1M +71.4% 1Y
Market cap
$18.36B
P/E
77.3x
Revenue (TTM)
$2.91B
Div. yield
0.00%
Life Sciences Tools Healthcare
1 win

Head to Head

11 decided of 12

Illumina leads on 6 of the 12 questions below (Illumina 6, Danaher 4, Revvity 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionILMNDHRRVTYLeader
Larger companyMarket capitalisation $43.30B $165.93B $18.36B DHR
Cheaper on earningsLower P/E, profitable companies only 52.5x 41.4x 77.3x DHR
Cheaper on forward earningsLower price / next fiscal year consensus EPS 57.9x 25.7x 32.4x DHR
Faster revenue growthRevenue growth, trailing twelve months +4.9% +4.6% +4.1% ILMN
More profitableNet margin, trailing twelve months 18.4% 15.9% 8.2% ILMN
Better return on capitalReturn on invested capital 15.1% 5.7% 3.1% ILMN
Less leveragedLower net debt / EBITDA 0.7x 2.9x 2.8x ILMN
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +195.3% +7.9% +71.4% ILMN
Better 5-year returnAnnualised price return, 5 years -6.5%/yr -5.6%/yr -1.3%/yr RVTY
Less volatileAnnualised volatility, 1 year 50.4% 30.6% 39.9% DHR
Higher overall scoreMean of the five percentile scores vs peers 65/100 60/100 58/100 ILMN

Percentile Scorecard

ILMNDHRRVTY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisILMNDHRRVTY
Valuation 50 #115 of 227 69 #72 of 227 68 #74 of 227
Growth 46 #119 of 219 22 #172 of 219 28 #158 of 219
Profitability 97 #8 of 205 88 #26 of 205 80 #41 of 205
Financial Health 51 #116 of 237 46 #129 of 237 47 #127 of 237
Shareholder Returns 83 #24 of 135 75 #34 of 135 66 #46 of 135
Overall 65 60 58
  • ILMN ranked among 247 companies in Medical Devices and Diagnostics
  • DHR ranked among 247 companies in Medical Devices and Diagnostics
  • RVTY ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodILMNDHRRVTYSPY
1 month +6.2%+2.9%+9.5% +0.9%
3 months +48.2%+19.1%+45.8% +5.9%
6 months +139.9%+30.9%+101.0% +8.5%
Year to date +120.2%+2.3%+70.9% +13.3%
1 year +195.3%+7.9%+71.4% +12.4%
3 years +171.8%+24.6%+69.0% +88.1%
3 years, per year +39.6%+7.6%+19.1% +23.5%
5 years -28.5%-24.9%-6.5% +68.2%
5 years, per year -6.5%-5.6%-1.3% +11.0%
10 years +114.2%+199.4%+225.5% +263.4%
10 years, per year +7.9%+11.6%+12.5% +13.8%

Risk

MeasureILMNDHRRVTYSPY
Volatility, 1Y 50.4%30.6%39.9% 12.7%
Downside volatility, 1Y 39.0%31.7%35.9% 12.7%
Beta vs S&P 500, 1Y 0.830.451.23 1.00
Return / volatility, 1Y 3.880.261.79 0.98
Max drawdown, 5Y -82.9%-50.8%-59.2% -25.4%
From 52-week high -1.7%-3.3%0.0% -0.9%
52-week high $293.69$242.05$165.36 $779.14
52-week low $95.03$161.91$82.26 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleILMNDHRRVTY
P/E now vs peer median 52.9xmedian 28.8x 41.2xmedian 28.8x 77.7xmedian 28.8x
P/S now vs peer median 9.7xmedian 3.0x 6.6xmedian 3.0x 6.3xmedian 3.0x
EV/EBITDA now vs peer median 38.5xmedian 17.4x 24.4xmedian 17.4x 26.6xmedian 17.4x
P/FCF now vs peer median 46.8xmedian 25.7x 30.1xmedian 25.7x 32.4xmedian 25.7x
P/B now vs peer median 15.4xmedian 2.4x 3.1xmedian 2.4x 2.6xmedian 2.4x
PEG now vs peer median 1.75median 1.03 -3.29median 1.03 -2.49median 1.03

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsILMNDHRRVTY
Revenue $4.49B $25.11B $2.91B
Gross profit $2.98B $14.69B $1.60B
Operating income $882.00M $5.13B $358.85M
Net income $825.00M $4.00B $237.55M
Free cash flow $931.00M $5.47B $568.85M
R&D $960.00M $1.62B $215.83M
EPS (diluted) $5.39 $5.66 $2.13
Cash & equivalents $1.04B $4.35B $1.02B
Total debt $1.99B $26.56B $3.21B
Shares (diluted) 153.00M 707.60M 111.63M
Enterprise value $38.07B $149.74B $14.63B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricILMNDHRRVTY
P/E 52.9x 41.2x 77.7x
P/FCF 46.8x 30.1x 32.4x
P/Operating cash flow 39.8x 24.8x 28.9x
P/S 9.7x 6.6x 6.3x
P/B 15.4x 3.1x 2.6x
P/Tangible book 18.0x 5.3x 3.7x
EV/EBITDA 38.5x 24.4x 26.6x
EV/EBIT 50.4x 36.4x 57.5x
EV/Revenue 9.9x 7.4x 7.1x
EV/FCF 47.7x 34.2x 36.3x
EV/Operating cash flow 40.6x 28.1x 32.3x
PEG (3Y EPS CAGR) 1.75 -3.29 -2.49

Growth

14 metrics
MetricILMNDHRRVTY
Revenue growth (1Y) 4.9% 4.6% 4.1%
Revenue CAGR (3Y) -1.0% -0.5% 0.9%
Gross profit growth (1Y) 4.6% 2.6% 2.3%
Gross profit CAGR (3Y) 2.9% -0.9% -0.4%
Operating income growth (1Y) -31.8% 16.1% -5.5%
Operating income CAGR (3Y) 28.3% -7.1% -3.7%
Net income growth (1Y) -34.4% 17.3% -16.7%
Net income CAGR (3Y) 30.0% -14.3% -33.8%
EPS growth (1Y) -32.7% 19.2% -12.3%
EPS CAGR (3Y) 30.1% -12.5% -31.2%
Operating cash flow growth (1Y) -5.1% 7.6% 6.2%
Operating cash flow CAGR (3Y) 38.1% -7.6% 86.9%
Free cash flow growth (1Y) -9.7% 12.4% 9.5%
Free cash flow CAGR (3Y) 105.0% -9.0% 64.8%

Profitability

14 metrics
MetricILMNDHRRVTY
Gross margin 66.4% 58.5% 55.0%
EBITDA margin 25.7% 30.5% 26.6%
Operating margin 19.6% 20.4% 12.3%
Pretax margin 22.6% 19.0% 9.0%
Net margin 18.4% 15.9% 8.2%
FCF margin 20.7% 21.8% 19.5%
Operating cash flow margin 24.4% 26.4% 21.9%
Return on equity 29.9% 7.6% 3.3%
Return on assets 12.5% 4.5% 2.0%
Return on invested capital 15.1% 5.7% 3.1%
Return on capital employed 17.5% 6.4% 3.3%
Asset turnover 0.7x 0.3x 0.2x
Cash conversion (OCF / net income) 1.3x 1.7x 2.7x
Stock comp / revenue 5.9% 1.2% 0.8%

Financial Health

11 metrics
MetricILMNDHRRVTY
Debt / assets 29.9% 28.8% 26.6%
Debt / equity 0.7x 0.5x 0.4x
Net debt / EBITDA 0.7x 2.9x 2.8x
Debt / FCF 2.1x 4.9x 5.6x
Liabilities / assets 57.3% 43.1% 40.0%
Equity / assets 42.7% 56.9% 60.0%
Interest coverage 8.9x 17.6x 3.7x
Current ratio 1.8x 1.7x 1.8x
Quick ratio 1.2x 1.0x 1.4x
Cash ratio 0.7x 0.5x 0.8x
Altman Z-score 8.19 3.74 3.45

Shareholder Returns

7 metrics
MetricILMNDHRRVTY
Dividend yield – 0.6% 0.2%
Net buyback yield 1.2% 1.8% 2.5%
Shareholder yield 1.2% 2.4% 2.7%
Payout ratio (earnings) – – 13.4%
Payout ratio (FCF) – – 5.6%
Dividend growth (1Y) – – -6.3%
Dividend CAGR (3Y) – – -6.1%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusILMNDHRRVTY
Forward P/E 57.9xFY2026 25.7xFY2026 32.4xFY2026
EPS, next fiscal year $4.99FY2026 $9.11FY2026 $5.10FY2026
EPS growth, next FY +3.1%FY2026 +16.8%FY2026 +0.8%FY2026
EPS growth, the year after +25.7% +8.0% +11.0%
Revenue, next fiscal year $4.52BFY2026 $27.01BFY2026 $2.98BFY2026
Revenue growth, next FY +4.1%FY2026 +9.9%FY2026 +4.0%FY2026
Revenue growth, the year after +12.0% -1.9% -2.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersILMNDHRRVTY
Held by institutions 100.0% 81.9% 100.0%
Institutions holding 933 2,117 545
Change in shares held, QoQ +0.0% +1.1% -1.3%
Institutions buying 463 839 301
Institutions selling 330 1,015 161
Buyers to sellers 1.40 0.83 1.87

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ILMNDHRRVTY
ILMN 1.00 0.33 0.51
DHR 0.33 1.00 0.51
RVTY 0.51 0.51 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ILMN, DHR and RVTY?

Danaher (DHR) is the largest by market capitalisation: Illumina (ILMN) $43.30B, Danaher (DHR) $165.93B, Revvity (RVTY) $18.36B.

Which stock is cheaper, ILMN, DHR and RVTY?

Danaher (DHR) trades on the lowest price-to-earnings ratio (Illumina (ILMN) 52.5x, Danaher (DHR) 41.4x, Revvity (RVTY) 77.3x). On next year's consensus earnings, Danaher (DHR) is cheapest (Illumina (ILMN) 57.9x, Danaher (DHR) 25.7x, Revvity (RVTY) 32.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Illumina (ILMN) grew revenue fastest over the trailing twelve months: Illumina (ILMN) +4.9%, Danaher (DHR) +4.6%, Revvity (RVTY) +4.1%.

Which company is more profitable?

Illumina (ILMN) has the highest net margin (Illumina (ILMN) 18.4%, Danaher (DHR) 15.9%, Revvity (RVTY) 8.2%). On return on invested capital, Illumina (ILMN) leads (Illumina (ILMN) 15.1%, Danaher (DHR) 5.7%, Revvity (RVTY) 3.1%).

Which stock has performed better?

Over the past year Illumina (ILMN) returned the most: Illumina (ILMN) +195.3%, Danaher (DHR) +7.9%, Revvity (RVTY) +71.4%. Over five years, Revvity (RVTY) compounded fastest (Illumina (ILMN) -6.5%/yr, Danaher (DHR) -5.6%/yr, Revvity (RVTY) -1.3%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Illumina (ILMN) 0.00%, Danaher (DHR) 0.00%, Revvity (RVTY) 0.00%. Illumina (ILMN) and Danaher (DHR) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Danaher (DHR) has been the steadiest (Illumina (ILMN) 50.4%, Danaher (DHR) 30.6%, Revvity (RVTY) 39.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ILMN, DHR and RVTY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Illumina (ILMN) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.